Every 10-Q that N2OFF, Inc. (NITO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NITO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NITO filings page.
Nexentis Technologies Inc. reported a much larger quarterly loss as it reshaped its business around oncology biotech and renewable energy projects. For the three months ended March 31, 2026, total assets were $16.4M and cash and cash equivalents were $4.3M.
The company posted an operating loss of $8.2M and a net loss of $6.6M, or $10.74 per basic share, driven mainly by a non‑cash goodwill impairment of $6.3M related to the MitoCareX oncology unit and higher share‑based compensation.
Nexentis closed the sale of its former Save Foods business, recognizing an $0.9M gain in discontinued operations, and received Voice Assist shares now valued at $1.7M. Management disclosed substantial doubt about the company’s ability to continue as a going concern beyond early 2027 without additional financing, despite having $6.5M of working capital and ongoing access to equity facilities.
N2OFF, Inc. (NITO) filed its Q3 2025 report, showing small quarterly profit but a year-to-date loss and a going concern warning. For the nine months ended September 30, 2025, the company recorded a net loss of $5.4 million. For the three months ended September 30, 2025, it reported a net gain of $370 thousand, helped by other income and fair value changes.
Cash and cash equivalents were $6.0 million as of September 30, 2025, with total assets of $11.0 million and total liabilities of $2.4 million. Management states there is substantial doubt about the company’s ability to continue as a going concern, though current cash is expected to fund operations until the end of Q3 2026.
The company effected a 1-for-35 reverse stock split on September 22, 2025. Shares outstanding were 1,371,541 as of September 30, 2025, and 2,712,883 as of November 13, 2025. N2OFF fully impaired its investment in Plantify as of September 30, 2025. It also continued building its renewable energy portfolio, including funding a solar PV/BESS joint venture, and closed the acquisition of MitoCareX on October 20, 2025, a subsequent event not included in the quarter’s results.
N2OFF, Inc. reported consolidated activity for the period ended June 30, 2025 showing sizable operating losses, continuing investments and multiple financing arrangements. The filing discloses a net loss from continuing operations of (5,809) and related consolidated net losses of similar magnitude, with loss per share from continuing operations of (0.28) basic and diluted amounts presented. The company completed equity issuances and warrant exercises that generated $1,500 of gross proceeds and recorded significant non-cash changes in fair value of warrant liabilities and investments (including a $7,000 change in warrant fair value). Material transactions include the acquisition/roll-up of MitoCareX (resulting in MitoCareX becoming a wholly-owned subsidiary upon issuance/transfer of ordinary shares) and loans or investments in Solar/SE/Solterra/Plantify and related credit facilities. The company disposed of NTWO OFF as a discontinued operation and recognized related cash and non-cash effects. The filing discloses multiple loans bearing 7%-8% and associated fair value adjustments, substantial share-based compensation, and warrants issued to lenders and service providers.